Inicio > Productos > Anticuerpos > Anticuerpos para Citometría de Flujo

Anti-Human PCSK9 Antibody (SAA0159), PerCP (HV275247)

Datasheet Compartir producto Copiar información

Precio(USD): $

Especificación:

50T
100T

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet

Vista general

Número de catálogo	HV275247
Descripción	Anti-Human PCSK9 Antibody (SAA0159), PerCP [SAA0159] (HV275247) is a human monoclonal antibody detecting PCSK9 in FCM. Suitable for Human. Highlights ●Flow Cytometry — Validated for flow cytometry applications. ●Fluorescent Label — Direct conjugate for streamlined workflows.
Reactividad de especies	Human
Aplicaciones	FCM
Especie huésped	Human
Isotipo	IgG4, kappa
ID de clon	SAA0159
Conjugación	PerCP
Clonalidad	Monoclonal
Objetivo	Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
Nivel de endotoxinas	Please contact with the lab for this information.
Número de acceso	Q8NBP7
Forma	Liquid
Buffer de almacenamiento	0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Store at 4°C for 12 months. Protect from light. Do not freeze.
Fondo	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha). 1. Poirier, S. et al. (2008) The Journal of biological chemistry 283, 2363-72. PMID: 18039658 2. Nassoury, N. et al. (2007) Traffic (Copenhagen, Denmark) 8, 718-32. PMID: 17461796 3. Fan, D. et al. (2008) Biochemistry 47, 1631-9. PMID: 18197702 4. Mayer, G. et al. (2008) The Journal of biological chemistry 283, 31791-801. PMID: 18799458 5. Chen, Y. et al. (2011) Biochemical and biophysical research communications 415, 515-8. PMID: 22074827 6. Jonas, MC. et al. (2008) EMBO reports 9, 916-22. PMID: 18660751
Nota	For flow cytometric staining, the suggested use of this reagent is 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. For research use only.

Imágenes

Referencias

Datasheet

Anti-Human PCSK9 Antibody (SAA0159), PerCP.pdf

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

=

Concentration

×

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

×

V₁ (Stock Vol.)

=

Working Solution

C₂ (Working Conc.)

×

V₂ (Working Vol.)

Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: support@abinScience.com

Lista de distribuidores

Anti-Human PCSK9 Antibody (SAA0159), PerCP